Cingulate Therapeutics LLC – Trademark Portfolio
Entity Type: 16
Cingulate Therapeutics LLC holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 5 trademarks are registered and 1 is pending. Notable registered marks include CTX, MASTERY, CINGULATE, and CINGULATE THERAPEUTICS. The owner is based in Kansas City, KS.
Suite 310
1901 W 47th Place
Kansas City, KS 66205
Showing of trademarks Trademarks
Trademark Classifications
Cingulate Therapeutics LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Cingulate Therapeutics LLC have?
Cingulate Therapeutics LLC has 15 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending, 9 abandoned.
What trademark classes does Cingulate Therapeutics LLC file in?
Cingulate Therapeutics LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Cingulate Therapeutics LLC's most well-known trademarks?
Cingulate Therapeutics LLC's registered trademark portfolio includes well-known marks such as CTX, MASTERY, CINGULATE, and CINGULATE THERAPEUTICS. These are among 5 currently registered trademarks in the portfolio.
What is Cingulate Therapeutics LLC's trademark registration success rate?
Cingulate Therapeutics LLC has a 36% trademark registration rate, with 5 out of 14 resolved applications resulting in successful registration. Currently, 1 application is pending review.